share_log

Allarity Therapeutics | 8-K/A: Current report (Amendment)

Allarity Therapeutics | 8-K/A: Current report (Amendment)

Allarity Therapeutics | 8-K/A：重大事件(修正)
美股SEC公告 ·  2024/09/10 21:18

Moomoo AI 已提取核心信息

Allarity Therapeutics announced significant corporate actions following its 2024 Annual Meeting on September 3. The company will execute a 1-for-30 reverse stock split effective September 11, 2024, at 12:01 a.m. ET. The split will automatically combine every 30 shares into one share, with fractional shares rounded up to the next whole number. The stock will continue trading under symbol "ALLR" on Nasdaq.The company also approved reducing its authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, stockholders approved expanding the 2021 Equity Incentive Plan share reserve from 2.17 million to 10.59 million shares.Other approved measures include the election of two Class II directors through 2027, ratification of Wolf & Company as auditor for 2024, and an amendment limiting certain officer liabilities under Delaware law. All seven proposals received sufficient stockholder approval at the annual meeting.
Allarity Therapeutics announced significant corporate actions following its 2024 Annual Meeting on September 3. The company will execute a 1-for-30 reverse stock split effective September 11, 2024, at 12:01 a.m. ET. The split will automatically combine every 30 shares into one share, with fractional shares rounded up to the next whole number. The stock will continue trading under symbol "ALLR" on Nasdaq.The company also approved reducing its authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, stockholders approved expanding the 2021 Equity Incentive Plan share reserve from 2.17 million to 10.59 million shares.Other approved measures include the election of two Class II directors through 2027, ratification of Wolf & Company as auditor for 2024, and an amendment limiting certain officer liabilities under Delaware law. All seven proposals received sufficient stockholder approval at the annual meeting.
Allarity Therapeutics在2024年9月3日的年度会议后宣布了重大企业行动。该公司将于2024年9月11日凌晨12:01执行1比30的反向拆股。拆股将自动将每30股合并为1股，碎股将向上四舍五入至下一个整数。股票将在纳斯达克继续以标的"ALLR"交易。该公司还批准将其授权股份从75050万减少至25050万，普通股授权从75000万减少至25000万股。此外，股东批准将2021年股权激励计划的股份储备从217万扩大至1059万股。其他批准的措施包括选举两名截至2027年的二级董事，批准Wolf & Company作为2024年的审计师，以及修订限制某些官员在特拉华州法律下的责任。所有七项提案在年度会议上都获得了足够的股东批准。
Allarity Therapeutics在2024年9月3日的年度会议后宣布了重大企业行动。该公司将于2024年9月11日凌晨12:01执行1比30的反向拆股。拆股将自动将每30股合并为1股，碎股将向上四舍五入至下一个整数。股票将在纳斯达克继续以标的"ALLR"交易。该公司还批准将其授权股份从75050万减少至25050万，普通股授权从75000万减少至25000万股。此外，股东批准将2021年股权激励计划的股份储备从217万扩大至1059万股。其他批准的措施包括选举两名截至2027年的二级董事，批准Wolf & Company作为2024年的审计师，以及修订限制某些官员在特拉华州法律下的责任。所有七项提案在年度会议上都获得了足够的股东批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！